Patent · US Active

Fibronectin based scaffold domain proteins that bind PCSK9

US9856309B2 · kind B2 · utility

7Cited by

22References

16Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

Ray Camphausen · Wayland, US
Jonathan Davis · Waltham, US
Sharon Cload · Cambridge, US
Fabienne M. Denhez · Arlington, US
Amna Saeed-Kothe · Dedham, US
Dasa Lipovsek · Pepperell, US
Ching-Hsiung Frederick Lo · Pennington, US
Chee Meng Low · Singapore, SG
Bowman Miao · Nazareth, US
Tracy S. Mitchell · Andover, US
Rex A. Parker · Titusville, US
Ginger Rakestraw · Cambridge, US
Katie A. Russo · Watertown, US
Doree F. Sitkoff · Dresher, US

Key dates

Filing date	Dec 2, 2015
Grant date	Jan 2, 2018
Priority date	—
Expiry date	Feb 11, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/70
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.